Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNSTNASDAQ:CORTNASDAQ:DRNANASDAQ:INSMNASDAQ:TBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ACORTCorcept Therapeutics$25.19-0.5%$23.34$20.87▼$34.28$2.62B0.47898,966 shs845,312 shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINSMInsmed$27.13-0.7%$27.79$16.25▼$32.00$4.06B0.921.46 million shs1.13 million shsTBPHTheravance Biopharma$8.97-0.4%$9.01$8.21▼$12.03$433.96M0.36358,452 shs401,710 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics-0.51%+1.78%+4.31%-22.44%+15.71%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INSMInsmed-0.70%+3.00%-7.18%-12.46%+58.28%TBPHTheravance Biopharma-0.44%+0.11%-7.43%-20.20%-16.32%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACORTCorcept Therapeutics4.6989 of 5 stars3.30.00.04.32.23.33.1DRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed3.915 of 5 stars3.51.00.04.43.30.80.6TBPHTheravance Biopharma1.9195 of 5 stars3.51.00.00.02.42.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation PharmaceuticalsN/AN/AN/AN/ACORTCorcept Therapeutics2.67Moderate Buy$33.7934.12% UpsideDRNADicerna PharmaceuticalsN/AN/AN/AN/AINSMInsmed3.00Buy$45.1066.24% UpsideTBPHTheravance Biopharma3.00Buy$20.00122.97% UpsideCurrent Analyst RatingsLatest DRNA, INSM, CORT, CNST, and TBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.002/27/2024INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$46.002/16/2024CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.002/15/2024INSMInsmedWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.001/8/2024TBPHTheravance BiopharmaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline1/2/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $28.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ACORTCorcept Therapeutics$482.38M5.41$0.95 per share26.44$4.92 per share5.12DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77INSMInsmed$305.21M13.20N/AN/A($2.32) per share-11.69TBPHTheravance Biopharma$57.42M7.52N/AN/A$4.28 per share2.10Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ACORTCorcept Therapeutics$106.14M$0.9526.5219.38N/A21.86%21.98%17.89%5/1/2024 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AINSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)TBPHTheravance Biopharma-$55.19M-$0.97N/AN/AN/A-96.12%-19.31%-12.03%5/13/2024 (Estimated)Latest DRNA, INSM, CORT, CNST, and TBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2024Q4 2023TBPHTheravance Biopharma-$0.15-$0.17-$0.02-$0.17$17.49 million$17.57 million2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million 2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39CORTCorcept TherapeuticsN/A4.394.31DRNADicerna PharmaceuticalsN/A2.462.46INSMInsmedN/A4.123.75TBPHTheravance BiopharmaN/A5.395.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/ACORTCorcept Therapeutics93.61%DRNADicerna Pharmaceuticals78.91%INSMInsmedN/ATBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%CORTCorcept Therapeutics19.80%DRNADicerna Pharmaceuticals10.20%INSMInsmed4.30%TBPHTheravance Biopharma5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableCORTCorcept Therapeutics352103.52 million83.02 millionOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableINSMInsmed373148.49 million142.11 millionOptionableTBPHTheravance Biopharma35948.17 million45.61 millionOptionableDRNA, INSM, CORT, CNST, and TBPH HeadlinesSourceHeadlineWhy Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?zacks.com - March 27 at 12:36 PMTheravance Biopharma (NASDAQ:TBPH) Shares Cross Below 50-Day Moving Average of $9.04americanbankingnews.com - March 26 at 5:14 AMTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04marketbeat.com - March 26 at 5:14 AMEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)marketbeat.com - March 18 at 1:27 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per Sharemarketbeat.com - March 15 at 7:48 AMJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)marketbeat.com - March 15 at 4:15 AMShort-Squeeze Showdown: 3 Stocks Ready to Crush the Skepticsinvestorplace.com - March 12 at 3:59 PMTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per Sharemarketbeat.com - March 8 at 6:18 AMAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potentialmarkets.businessinsider.com - March 7 at 9:55 AMFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)marketbeat.com - March 7 at 7:53 AMTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestonesmarkets.businessinsider.com - February 28 at 10:50 AMTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:50 AMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatestockhouse.com - February 27 at 11:30 PMTheravance Biopharma Inc (TBPH)investing.com - February 27 at 1:29 PMTheravance's (TBPH) Q4 Earnings & Revenues Surpass Estimateszacks.com - February 27 at 12:51 PMBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharmamarkets.businessinsider.com - February 27 at 1:45 AMTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03Mmsn.com - February 26 at 8:44 PMTheravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimateszacks.com - February 26 at 6:26 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - February 26 at 4:05 PMTheravance Biopharma Q4 2023 Earnings Previewseekingalpha.com - February 25 at 6:21 PMTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and Datesbenzinga.com - February 24 at 9:19 AMTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03msn.com - February 24 at 9:19 AMTheravance Biopharma to Participate in an Upcoming Investor Conferenceprnewswire.com - February 22 at 6:00 AMWill Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?finance.yahoo.com - February 15 at 10:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsConstellation PharmaceuticalsNASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Theravance BiopharmaNASDAQ:TBPHTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.